देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
ITRACONAZOLE
MINT PHARMACEUTICALS INC
J02AC02
ITRACONAZOLE
100MG
CAPSULE
ITRACONAZOLE 100MG
ORAL
30
Prescription
AZOLES
Active ingredient group (AIG) number: 0123311002; AHFS:
APPROVED
2017-03-22
_Approved Product Monograph _ MINT-ITRACONAZOLE (itraconazole) _ _ _Page 1 of 55_ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATIO N PR MINT-ITRACONAZOLE Itraconazole Capsules Capsule, 100 mg, Oral Antimycotic for systemic use, triazole and tetrazole derivatives Mint Pharmaceuticals Inc. 6575 Davand Drive, Mississauga, Ontario, L5T 2M3 Date of Initial Authorization: March 22, 2017 Date of Revision: May 17, 2023 Submission Control Number: 270537 _Approved Product Monograph _ MINT-ITRACONAZOLE (itraconazole) _ _ _Page 2 of 55_ _ _ RECENT MAJOR LABEL CHANGES 2. CONTRAINDICATIONS 05/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ......................................................................................... 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................. 4 1 INDICATIONS ................................................................................................................. 4 1.1 Pediatrics ......................................................................................................... 4 1.2 Geriatrics ......................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................. 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ......................................................... 6 4 DOSAGE AND ADMINISTRATION ................................................................................. 7 4.1 Dosing Considerations ..................................................................................... 7 4.2 Recommended Dose and Dosage Adjustment ................................................. 7 4.4 Administration ...................................... पूरा दस्तावेज़ पढ़ें